CN Patent

CN117203208A — 靶向活化与失活态kras g12d的抑制剂

Assigned to Tsinghua University · Expires 2023-12-08 · 2y expired

What this patent protects

一种吡啶并嘧啶化合物、含有其的药物组合物及其制备方法和用途，所述化合物可以靶向活化与失活态KRAS G12D，作为KRAS G12D突变蛋白的可逆抑制剂。

USPTO Abstract

一种吡啶并嘧啶化合物、含有其的药物组合物及其制备方法和用途，所述化合物可以靶向活化与失活态KRAS G12D，作为KRAS G12D突变蛋白的可逆抑制剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN117203208A
Jurisdiction
CN
Classification
—
Expires
2023-12-08
Drug substance claim
No
Drug product claim
No
Assignee
Tsinghua University
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.